EUCTR2012-000773-23-BG进行中（未招募）不适用
Study of the Safety and Efficacy of LY2623091 in Chronic Kidney Disease Patients - MRAC
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1] Men and women of non-childbearing potential as determined by medical history and PE.
- •[1a] male subjects: agree to use 2 medically accepted methods of contraception
- •[1b] female subjects: women not of child-bearing potential
- •[2] Have been diagnosed with CKD
- •3] Have an estimated glomerular filtration rate (eGFR) between 30-70 ml/min/1.73 m2
- •4] Have been taking an ACE inhibitor and/or ARB, for at least 3 months, and at a stable dose for =2 months prior to randomization
- •5] Stable use of BP medication and acceptable cuff BP
- •6] Have serum potassium =5.0 mEq/L (equivalent to mmol/L) at screening, and no more than 1 hospitalization due to hyperkalemia within 1 year
- •[7] Are 18-75 years old, inclusive
- •8] Have given written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 24
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 24
排除标准
- •Patients who are currently enrolled in, or have discontinued within the last 30 days or 5 half lives (whichever is longer) of the investigational drug from, a clinical trial involving an investigational drug or device or an off-label use of an approved drug
- •Patients who have previously completed or withdrawn from this study or any other study investigating LY2623091.
- •Patients who are taking any diuretic drug and not receiving a stable dose for 3 weeks prior to the screening/qualification visit and through end of treatment
- •Patients receiving a renin inhibitor, or an MR antagonist must have a wash-out period of at least 1 month prior to randomization.
- •Patients in whom dialysis or renal transplantation is anticipated by their physician within 6 months after the screening visit.
- •Patients with a history of acute kidney injury within 3 months before the screening visit.
- •Patients who have or are expected to require systemic immunosuppression therapy within 30 days of the screening visit (except for inhalant steroids).
- •Patients who use oral or parenteral corticosteroids within 30 days of the screening visit.
- •Patients with a diagnosis of Class III or IV congestive heart failure
- •Patients with evidence of human immunodeficiency virus (HIV) and/or positive human HIV antibodies; patients with a history of cirrhosis or hepatitis C or are positive for hepatitis C antibody at the screening visit; patients who are known to be hepatitis B surface antigen-positive or are positive for hepatitis B surface antigen at the screening visit.
- •Patients who use CYP3A4 inhibitors or inducers, potassium-sparing diuretic drugs, potassium supplements or systemic glucocorticoids within 7 days of study enrollment. Intermittent use of nonsteroidal antiinflammatory drugs (NSAIDs) is permitted, except for within 24 hours of critical urine sodium/potassium measures or during the inpatient periods, during which times NSAID use is limited to chronic use only (stable for =1 month prior to enrollment). Prostaglandin inhibitors should not be used during the inpatient periods of the study, with above exception of chronic NSAID use.
- •Patients who have donated blood of more than 500 mL within the last 60 days prior to screening.
- •Patients who have an average weekly alcohol intake that exceeds 21 units per week or subjects unwilling to stop alcohol within 48 hours of entry into study and for the duration of the study
- •Patients who consume natural licorice and/or natural licorice-containing products and/or regular daily consumption of grapefruit and/or grapefruit juice within 7 days of first dosing and/or anticipated consumption during the study.
研究者
相似试验
进行中（未招募）
1 期
Study of the Safety and Efficacy of LY3016859 after Multiple Dosing in Diabetic PatientsEUCTR2012-004496-40-GBEli Lilly and Company60
进行中（未招募）
不适用
Study of the Safety, and efficacy after Multiple Dosing in Diabetic PatientsChronic kidney disease associated with Diabetic nephropathyMedDRA version: 16.1Level: LLTClassification code 10064848Term: Chronic kidney diseaseSystem Organ Class: 100000004857MedDRA version: 16.1Level: LLTClassification code 10012678Term: Diabetic nephropathy NOSSystem Organ Class: 100000004857EUCTR2012-004496-40-BGEli Lilly and Company64
进行中（未招募）
不适用
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination with Atorvastatin, Simvastatin, and Rosuvastatin in Patients with Hypercholesterolemia or Low HDL-CEUCTR2009-017479-29-DKEli Lilly and Company400
进行中（未招募）
不适用
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination with Atorvastatin, Simvastatin, and Rosuvastatin in Patients with Hypercholesterolemia or Low HDL-CHypercholesterolemia or Low HDL-CMedDRA version: 12.1Level: LLTClassification code 10020604Term: HypercholesterolemiaMedDRA version: 12.1Level: LLTClassification code 10024915Term: Low HDEUCTR2009-017479-29-NLEli Lilly and Company400
尚未招募
2 期
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination with Atorvastatin, Simvastatin, and Rosuvastatin in Patients with Hypercholesterolemia or Low HDL-C.Low HDL-C and Hypercholesterolemia10013317NL-OMON36417Eli Lilly60